Evoke Wealth’s Esperion Therapeutics ESPR Stock Holding History

Evoke Wealth’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-20	Closed	-$733	–	1310
2019 Q3	$733	Buy	+20	New	+$792	﹤0.01%	1334

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Evoke Wealth's ESPR Position: Q4 2019 in Review

Evoke Wealth sold out of Esperion Therapeutics (ESPR) in Q4 2019, closing a stake of 20 shares — an estimated $733 sold.

Evoke Wealth first reported a position in ESPR in Q3 2019 and held it in 1 quarter. The position peaked at $733 in Q3 2019. 172 funds tracked by Wall St. Rank hold ESPR as of Q4 2019.

Evoke Wealth reported no remaining Esperion Therapeutics position as of Q4 2019 after selling out during the quarter.
Evoke Wealth sold 20 Esperion Therapeutics shares in Q4 2019, an estimated $733.
Evoke Wealth first reported a position in Esperion Therapeutics in Q3 2019 and held it in 1 quarter.
Evoke Wealth's Esperion Therapeutics position peaked at $733 in Q3 2019.
172 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2019.

Based on Evoke Wealth's 13F filing for Q4 2019, filed 7 Feb 2020.